Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04238793 · ClinicalTrials.gov registry record · Phase 1
Single Ascending Doses Study of KLS-2031 in Subjects With Neuropathic Pain From Lumbosacral Radiculopathy
A Phase 1 study, sponsored by Kolon Life Science.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT04238793 is a Phase 1 study that has completed, run by Kolon Life Science. The registered enrollment target is 18 participants.
The verdict
NCT04238793, a Phase 1 study, has completed, sponsored by Kolon Life Science.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
Escalating single-dose design study to determine the safety, tolerability, and analgesic activity of KLS-2031
Interventions
- OTHER Placebo
- DRUG KLS-2031
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2020-04-16 |
| Est. Completion | 2023-10-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04238793
The ClinicalTrials.gov registry entry for NCT04238793 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kolon Life Science, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04238793 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04238793 about?
NCT04238793 is a clinical study titled "Single Ascending Doses Study of KLS-2031 in Subjects With Neuropathic Pain From Lumbosacral Radiculopathy". Escalating single-dose design study to determine the safety, tolerability, and analgesic activity of KLS-2031
What is the current status of trial NCT04238793?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2020-04-16. Estimated completion is 2023-10-18.
What interventions are being tested in trial NCT04238793?
The interventions under investigation include: Placebo (OTHER), KLS-2031 (DRUG).
Who is sponsoring clinical trial NCT04238793?
This trial is sponsored by Kolon Life Science, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.